Clinical Trials Logo

Lung Diseases, Obstructive clinical trials

View clinical trials related to Lung Diseases, Obstructive.

Filter by:

NCT ID: NCT06390345 Not yet recruiting - Clinical trials for Chronic Obstructive Pulmonary Disease

Functional Improvement in OSA and COPD With a Telehealth LifeStyle and Exercise Intervention

FOCuSEd
Start date: May 1, 2024
Phase: N/A
Study type: Interventional

We will conduct a Type I hybrid effectiveness-implementation study to test an integrated telehealth intervention among 400 overweight and obese patients with COPD and OSA. We will include eligible participants receiving primary care at one of five Department of Veterans Affairs (VA) medical centers and their community-based outpatient clinics. We will randomize patients in a 1:1 ratio to the multi-component intervention or "enhanced" usual care, stratifying by age (≥65 vs. < 65) and site. Participants randomized to the intervention will receive an integrated, telehealth-delivered intervention composed of a self-directed lifestyle program and supervised pulmonary rehabilitation. At the end of 3 months, we will offer to enter a recommendation for weight management medications on behalf of eligible intervention participants. In the post-core period (months 4-12), participants will continue to have as-needed access to the lifestyle coach. For participants randomized to the "enhanced" usual care group, study staff will prompt the patient's primary care provider to refer them to existing weight loss management and pulmonary rehabilitation programs. Follow-up will occur at virtual visits at 3 and 12 months. Our primary effectiveness outcome at 1-year is quality of life measured by the SF-12 Physical Component Summary Score. Secondary effectiveness outcomes will include other measures of quality of life (including sleep related impairment), sleep disturbance, disease severity (COPD exacerbations and respiratory event index for OSA), depression, social support, weight loss and cardiovascular risk. In addition to assessing effectiveness, we will also conduct a concurrent implementation process evaluation using the RE-AIM framework.

NCT ID: NCT06389734 Completed - Clinical trials for Chronic Obstructive Pulmonary Disease

Combining Manual Soft Tissue Release and Exercise Training in COPD: the Effect on LF, EC, and CAF

Start date: March 2, 2023
Phase: N/A
Study type: Interventional

The potential effects of combining manual soft tissue release and physical exercise training on lung function, exercise capacity, and cardiac autonomic function in patients with moderate and severe chronic obstructive pulmonary disease were investigated.

NCT ID: NCT06385301 Not yet recruiting - Clinical trials for Lung Diseases, Obstructive

Exercise Performance on Ambient Air vs. Low-Flow Oxygen Therapy With Chronic Lung Diseases

Start date: May 2024
Phase: N/A
Study type: Interventional

The investigators aim to study the effect of SOT in subjects with chronic lung disease in submaximal exercise.

NCT ID: NCT06381973 Recruiting - Healthy Clinical Trials

Ventilation Distribution in COPD Patients During Breathing Exercises

Start date: April 15, 2024
Phase: N/A
Study type: Interventional

ELTGOL (Slow Expiration with the Opened Glottis in the Lateral posture) is an airway clearance technique performed in the lateral decubitus position. This technique focuses on optimizing ventilation of the infralateral lung (when the subject is lying in the lateral posture) to enhance local air-liquid interaction. Previous studies on ventilation differences between the infra- and supralateral lungs were conducted on healthy, young, male subjects, without the application of thoracic or abdominal pressure. This study aimed to assess ventilation distribution in right lateral recumbency in patients with chronic obstructive pulmonary disease (COPD), as well as healthy individuals, and investigate the impact of thoracic and abdominal manual pressures during ELTGOL on ventilation distribution.

NCT ID: NCT06377410 Not yet recruiting - Clinical trials for Chronic Obstructive Pulmonary Disease

Efficacy & Safety of Dry Powder Ivy Extract (Syrup Prospan) Versus NAC Among COPD Patients

SyProNAC
Start date: May 1, 2024
Phase: N/A
Study type: Interventional

As the third global leading cause of death, Chronic Obstructive Pulmonary Disease (COPD) affects more than 300 million people worldwide. These patients suffer from 0.5-3.5 exacerbations per year on average. Each exacerbations dampened their health status as well as quality of life, not to mention a great burden to our healthcare system. Those partially treated or prolonged exacerbations would subsequently lead to unfavorable disease progression. Hence a holistic approach in managing each exacerbations is very crucial. Mucus hypersecretion in COPD patients plays a pivotal role in acute exacerbations and associated with unfavorable outcomes. These exacerbations comes with sputum increment as much as its purulence. Mucolytics are believed to to ease patient to expectorate and benefits them from tip into an exacerbations or even the consequent hospitalisation. Mucolytics work by reducing sputum viscosity hence improved its expectoration. N-acetylcysteine (NAC) is a mucolytic with antioxidant and anti-inflammatory properties, commonly used in practice among COPD patients. Meanwhile, Syrup Prospan is ivy leaf preparations, obtained as extracts from leaves of the plant Hedera helix L. It is widely used over-the-counter cough remedy containing saponins which are believed to have expectorant properties. Studies show evidence of antispasmodic, bonchodilating, anti-inflammatory and antitussive properties and its usage is authorised by the European Medicines Agency .

NCT ID: NCT06376994 Not yet recruiting - Clinical trials for Chronic Obstructive Pulmonary Disease (COPD)

Multi-Center Clean Air Randomized Controlled Trial in COPD

Clean Air
Start date: September 2024
Phase: Phase 3
Study type: Interventional

This is a multi-center randomized, sham-controlled clinical trial to determine the effectiveness of an air cleaner intervention aimed at improving indoor air quality on reducing COPD exacerbation risk and improving quality of life, functional status, rescue medication use.

NCT ID: NCT06368427 Recruiting - Clinical trials for Chronic Obstructive Pulmonary Disease (COPD)

Change in Patient-repOrted Outcomes in COPD Patients Newly Initiated on TRIXEO AEROSPHERE in Real worlD

COnCORD
Start date: April 30, 2024
Phase:
Study type: Observational

The purpose of this study is to describe patients' clinical and self-reported outcomes of treatment with budesonide / glycopyrronium / formoterol Metered dose inhaler (BGF MDI) in Romania in real-life setting, up to 6 month of observation period. The study will focus primarily on the change in self-perceived health status in the first 12 weeks (3 months) of treatment with no pre-defined hypothesis.

NCT ID: NCT06366113 Recruiting - Clinical trials for Respiratory Diseases

Time of Exercise Re-training With Chronic Obstructive Pulmonary Disease (COPD)

CHRONOBIO
Start date: January 2, 2024
Phase: N/A
Study type: Interventional

Pulmonary rehabilitation (PR) is an effective intervention for reducing hospital readmissions, secondary events, and mortality in patients with respiratory pathologies. The program should not be improved by introducing new subjects such as circadian rhythm.

NCT ID: NCT06361862 Recruiting - Cancer Clinical Trials

Does Continuous Vital Sign Monitoring Increase Investigations and Interventions in Complication-free Patients?

WARD-OT
Start date: January 1, 2024
Phase: N/A
Study type: Interventional

This aim of this study is to investigate whether active alerts during CVSM result in an increased number of diagnostic tests and treatments in complication free patients, hypothesizing that more interventions are performed in the CVSM-group than standard of care (EWS) group.

NCT ID: NCT06358235 Recruiting - Clinical trials for Chronic Obstructive Pulmonary Disease

The Effect of Music Therapy on Dyspnea Severity and Vital Signs

Start date: January 7, 2024
Phase: N/A
Study type: Interventional

This study aims to investigate the effect of music therapy on dyspnea severity and quality of life indicators in patients with Chronic Obstructive Pulmonary Disease (COPD) admitted to the intensive care unit. The study will be conducted at Isparta City Hospital and Kumluca State Hospital in Antalya, Turkey, using an experimental design. Patients will be divided into experimental and control groups, selected using randomization. Patients in the experimental group will receive music therapy in the Hüseyni maqam, while those in the control group will not receive any music therapy. Life indicators and Modified Borg Scale (MBS) values of patients in the experimental group will be recorded before, immediately after, and 30 minutes post-application. Music therapy will be administered to patients for only one day, once in the morning. Data for patients in the control group will be collected at the same time intervals. The results of this study aim to contribute to the literature on the impact of music therapy on dyspnea severity and quality of life indicators in COPD patients.